



Dexa Group
Recognition
As proof of our commitment to public health, Dexa Group's globally standardized quality has earned official recognition—reflecting our quality, integrity, and dedication to delivering high-value innovation.


Dexa: A Snapshot
0
Employees
0
Patents
0
Trademarks
0
Pharmacies Covered Directly
0
International Alliances
0
Marketing Authorisations
Latest News
PT Ferron Par Pharmaceuticals just won two investment awards from the West Java Provincial Government at The 8th West Java Investment Summit (WJIS) 2026. The two categories won are Best Domestic Direct Investment (PMDN) and Highest Domestic Direct Investment (PMDN) Value. The Best PMDN award was received directly by PT Ferron Par Pharmaceuticals Director Benny Sutisna Suwarno, while the Highest PMDN Investment Value award was accepted by Operations Director Budi Yuwono. The awards were...
20 November 2026
Independent accreditation strengthens confidence in the scientific evidence supporting DLBS-developed Inlacin® as the global transition from PCOS to polyendocrine metabolic ovarian syndrome (PMOS) brings greater attention to the condition's endocrine and metabolic dimensions.
19 November 2026
PT Beta Pharmacon, part of Dexa Group, is contributing to the independence of the national pharmaceutical industry by manufacturing Multi Micronutrient Supplements (MMS) formulated in accordance with the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) standard in Indonesia.
17 November 2026
Years of dedication to research and scientific advancement have earned Prof. Raymond R. Tjandrawinata, Molecular Pharmacologist at Dexa Group, a place among the top 7.9% of researchers in the Top 1000Scholar 2026 ranking.
9 November 2026
Dexa Group has once again received the prestigious Primaduta Award from the Ministry of Trade of the Republic of Indonesia. The 2026 award was presented to Glorious Dexa Mandaya Philippines—Dexa Medica’s operational entity in the Philippines—in the "Export Supporting Diaspora" category, recognizing its key contributions to expanding the market for Indonesian products in the Philippines.
15 October 2026
JAKARTA — PT Fonko International Pharmaceuticals has recorded several key milestones in the development of oncology drug manufacturing in Indonesia. These achievements include securing European Union Good Manufacturing Practice (EU GMP) certification in 2025, developing a range of “first copy” products for cancer therapy, and obtaining halal certification for its entire oncology product line. This progress builds on Fonko’s ongoing commitment to expanding domestic production capacity for...
1 October 2026




























